TNF and rheumatoid arthritis: The benefits of AR786 for histopathological endpoints in the CIA model are similar to those seen with TNF-alpha blockade, IL-1RA or methotrexate [39, 40], although further research would be required to determine the potential of TrkA inhibition for RA disease modification.